

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : AUGUSTYN, et al.

Serial No.: 10/565,515

Art Unit: 3771

Filing Date: January 23, 2006

Examiner: Ostrup, Clinton T.

For: MEDICAMENT DISPENSER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

This is filed concurrently with a Request for Continued Examination. The Commissioner is authorized to charge any fee due in connection with this filing, or credit any overpayment, to Deposit Account No. 07-1392.

Amendment is set forth here on Page 2.

Amendment to Inventorship:

Please amend the inventorship such that these people are the only named inventors:

Paul Rand
Michael Davies
Stephen Augustyn
Stephen Harvey

The following individuals should be deleted:

Mark Palmer
Alan Wilson

REMARKS

This is filed concurrently with a Request for Continued Examination and an Information Disclosure Statement.

Additionally, pursuant to 37 C.F.R. 1.48(b)(1), Applicants request amendment of inventorship and acknowledges that the deleted inventor's contribution is no longer being claimed in this application. In this instance, Mark Palmer and Alan Wilson are no longer inventors.

Respectfully Submitted,

/Robert J. Smith/
Robert J. Smith
Agent of Record
Registration No. 40,820

Date: June 21, 2011
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-9616
Facsimile: (919) 483-7988